Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence

Phase 2

Completed

Conditions: Alcohol Dependence
PTSD

Interventions: Drug: Placebo
Drug: Propranolol

Registration Number: NCT01055171

Lead Sponsor: Medical University of South Carolina

Brief Summary: The purpose of this study is to examine the effect of propranolol versus placebo on craving, distress and cue reactivity to trauma and alcohol cues.

Detailed Description: Summary and Synthesis: Epidemiological studies have established the occurrence of high rates of AD in persons with PTSD. Likewise, studies of alcohol/drug abuse treatment seekers have documented high rates of trauma exposure and PTSD. The high prevalence of PTSD/AD comorbidity is the cause of enormous human suffering, most of which either goes untreated or is resistant to treatment efforts. Both theory and research concerning the interface between these two disorders suggests that PTSD is associated with the initiation of excessive alcohol use and/or the development of AD by way of an escape/avoidance behavioral mechanism wherein escalating alcohol use is reinforced by its ability to dampen the negative emotions and arousal associated with PTSD. If PTSD is often a primary cause of the initiation and maintenance of AD, then clinical interventions that primarily impact PTSD should lead to significant improvements in craving for, and use of, alcohol. The findings of two recent treatment studies offer especially compelling support for this expectation. Drawing on both basic neuroscience research and a developing body of suggestive clinical/applied research, we were led to consider if the putative memory modulating properties of the adrenergic antagonist propranolol might have therapeutic benefits for PTSD/AD comorbid individuals. Thus, the proposed study will test the hypothesis that the strategic administration of propranolol coupled with the elicitation/retrieval of trauma-related memories will dampen emotional distress, alcohol craving and cue reactivity during subsequent exposure to trauma- and alcohol-related cues. A two-week follow-up laboratory session and clinical assessment will permit us to evaluate whether treatment benefits are maintained over time and if there are any changes in alcohol use and PTSD symptomatology.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 44

Inclusion Criteria

Participants must meet DSM-IV criteria for current alcohol dependence
Participants must have experienced criminal victimization
Use of birth control by female participants
Live within a 50-mile radius of research site
Consent to remain abstinent of all drugs and alcohol for 24 hours prior to patient admission and follow-up
Consent to random assignment to propanol or placebo
Individuals must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.

Exclusion Criteria

Women who are pregnant, nursing or are of childbearing potential and not using birth control.
Evidence or history of significant hematological, endocrine, cardiovascular, pulmonary, renal, gastrointestinal or neurological disease
Significant liver impairment
Currently taking anti-arrhythmic agents, psychostimulants or other agents known to interfere with heart rate and skin conductance monitoring.
Known or suspected hypersensitivity to propanol
Individuals taking medication that could adversely interact with the study medication, including the following: albuterol, insulin or significant inhibitors of CYP2D6
Individuals with bronchial asthma or chronic obstructive pulmonary disease
Prospective participants will be excluded if they are currently receiving exposure-based therapy for PTSD.
Individuals with a history of or current psychotic disorder.
Individuals with Addison's disease, Cushing's disease or other diseases of the adrenal cortex likely to affect cortisol levels.
Individuals receiving synthetic glucocorticoid therapy, any exogenous therapy, or treatment with other agents that interfere with HPA axis function within one month of the time of testing.
Individuals with resting heart rates less than 55 bpm.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Patient to receive placebo in this condition.
Propranolol	Propranolol	Patients will receive Propranolol in this condition.

Primary Outcome Measures

Name	Time	Method
Retrieval Session Distress Scores (Session 1)	Multiple times throughout cue exposure during retrieval session (Session 1)	Found by using our Single Item Distress (SID) scale. A study team member asks the participant to verbally report the level of distress they were experiencing using values between 0 and 100, with 0 representing no distress and 100 extreme distress.
Retrieval Session Craving Scores (Session 1)	Multiple times throughout cue exposure during retrieval session (Session 1)	Found by using our Single Item Craving (SIC) scale. A study team member asks the participant to verbally report the level of craving they were experiencing using values between 0 and 100, with 0 representing no craving and 100 extreme craving for alcohol.
Test Session Distress Scores (Session 2)	Multiple times throughout cue exposure during test session (Session 2)	Found by using our Single Item Distress (SID) scale. A study team member asks the participant to verbally report the level of distress they were experiencing using values between 0 and 100, with 0 representing no distress and 100 extreme distress.
Test Session Craving Scores (Session 2)	Multiple times throughout cue exposure during test session (Session 2)	Found by using our Single Item Craving (SIC) scale. A study team member asks the participant to verbally report the level of craving they were experiencing using values between 0 and 100, with 0 representing no craving and 100 extreme craving for alcohol.

Secondary Outcome Measures

Name	Time	Method
Proportion of Drinking Days	90 days prior to participation in study up to 2-week follow up session (Session 3)	Proportion of drinking days from 90 days prior to the screening to the follow-up period.